StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note released on Wednesday. The firm issued a hold rating on the stock.

Other equities analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Ekso Bionics in a research note on Tuesday, January 14th. Lake Street Capital dropped their target price on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th.

Ekso Bionics Price Performance

Shares of EKSO opened at $0.64 on Wednesday. The firm has a market capitalization of $14.17 million, a price-to-earnings ratio of -0.99 and a beta of 1.47. The firm’s fifty day simple moving average is $0.67 and its 200-day simple moving average is $0.93. Ekso Bionics has a twelve month low of $0.50 and a twelve month high of $2.42. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The business had revenue of $4.13 million during the quarter, compared to analyst estimates of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same quarter in the prior year, the business earned ($0.24) earnings per share. Equities analysts forecast that Ekso Bionics will post -0.48 EPS for the current fiscal year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.